Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 83.6%

Neg 0% Neu 0% Pos 83.6%

Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $42 to $45.